gdc
FDA Approvals, News & UpdatesLeukemiaNewsworthy

Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

December 2017 Vol 3 No 6

On August 17, 2017, the FDA approved the targeted therapy Besponsa (inotuzumab ozogamicin; from Pfizer) for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

This approval was based on a clinical trial that showed complete response to therapy with Besponsa in more than one-third of patients who received the drug. Serious side effects include liver toxicity, such as veno-occlusive disease or sinusoidal obstruction syndrome, as well as increased risk of death if used after certain stem-cell transplants.

Share this:

Recommended For You
CLL Monthly MinutesLeukemia
The Impact of COVID-19 on Patient–Doctor Communication
Although the use of telemedicine has been increasing due to the COVID-19 pandemic, it has not completely replaced the need for in-person visits.
CLL Monthly MinutesLeukemia
Fewer Surprise Medical Bills Starting in 2022
A federal law protects consumers from receiving bills covering the balance of many out-of-network emergency medical services.
CLL Monthly MinutesLeukemia
Improved Combination Therapies May Be Coming for Patients with CLL
Combined acalabrutinib, venetoclax, and obinutuzumab have shown favorable efficacy and tolerability in untreated patients in an ongoing phase 2 study.
CLL Monthly MinutesLeukemia
Evolving Cancer Care in the Time of COVID-19
The need to protect patients and healthcare workers from contracting COVID-19 has resulted in many changes to how hospital care is delivered.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country